CutisPharma adds drug manufacturing to its operations

CutisPharma, a specialty pharma company with a background in selling kits used by retail pharmacies to compounded medications, has now gotten into the manufacturing side of things itself. The company kicked off new manufacturing operations at its Wilmington, MA, headquarters on Wednesday. A spokesman said CutisPharma invested $4 million in the FDA GMP-compliant facility and is in the process of hiring. It has already added 15 people, bringing its total to 50, and expects to add up to 100 more as its moves for FDA approval of applications for generic drugs. It has worked with contract manufacturers in the past, the spokesman said. Release

Suggested Articles

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.